Introduction
Pathways and different risk factors involved in melanoma occurrence and development
MAPK and AKT signaling pathways
BRN2 expression
Hypoxia-inducible factor-1 alpha
Src and STAT3 signaling
Ambra1 protein
Gene | Gene type | Function | Comment | Refs. |
---|---|---|---|---|
MC1R | Oncogenic | The eumelanin pigments (dark brown pigments) are synthesized in response to UV exposure by this receptor | The high expression leads to the more frequent cell division | [66] |
CDK4 | Oncogenic | Contributing to the regulation of cell cycle | Triggering metastasis inducing pathways and also, interfering the phosphorylation of pRB (retinoblastoma protein) in the mid-G1 phase | [55] |
BRAF | Oncogenic | Contributing to regulating cell division and differentiation as a part of the family of signal transduction protein kinases | Activating the MAPK pathway involved besides RAF and the RAS family | [67] |
CCND1 | Oncogenic | In a manner dependent on cyclin-dependent kinases, or CDKs, promote progression of G1-S phase of the cell cycle by inactivating the RB protein | Contributing to the phosphorylation of pRB by binding to CDK4 | [68] |
RAS and NRAS (neuroblastoma RAS viral oncogene homolog) | Oncogenic | Regulating cell division by encoding N-Ras protein as GDP–GTP-regulated binary on–off switches | Activation of MAPK and the phosphatidylinositol 3-kinase (PI3K) pathway | |
c-KIT | Oncogene | Interacting with stem cell factor (SCF), activating downstream signaling molecules, causing the expression of certain genes, regulating cell differentiation and proliferation, and restraining cell apoptosis, associated with tumor formation, development, migration, and recurrence | Induction of both MAPK and PI3K-AKT kinase pathways | [70] |
GNAQ (guanine nucleotide-binding protein G(q)) and GNA11 (guanine nucleotide-binding protein subunit α-11) | oncogene | Making a guanine nucleotide-binding protein G(q) subunit alpha (Gαq) to activate downstream cellular signaling pathways | Encoding G-protein alpha subunit q and alpha subunit 11, respectively | [71] |
P53 | tumor suppressor gene | controlling cell division and cell death in the cell’s nucleus | Associated with advanced-stage disease | [72] |
TP 53 | tumor suppressor gene | Encoding P53 protein as a tumor suppressor by keeping cells from growing and dividing | A somatic mutation causing abnormal p53 expression | [73] |
P16 | tumor suppressor gene | As a CDK inhibitor; it slows down the progression of the cell cycle | Effecting G1 cyclin-dependent kinases cell regulator | [74] |
BCORL1 | tumor suppressor gene | Encode a transcriptional corepressor binding to promotor regions of DNA binding proteins | Represseing E-cadherin expression via interaction with CtBP | [75] |
PPP2R3B (gonosomal protein phosphatase 2 regulatory subunit B, beta) | tumor suppressor gene | As a major family of Ser/Thr phosphatase gene negatively control cells growth and division | Intervening with DNA replication and cell cycle progression by its regulatory subunit PR70 | [76] |
RASA2 (RAS p21 protein activator 2) | tumor suppressor gene | Encode RasGAP as a tumor suppressor | Activation of RAS GTPase, increase RAS activation, and melanoma cell growth | [77] |
PTEN | tumor suppressor genes | Regulate cell division by keeping cells from growing and dividing | Elimination of negative regulating on downstream components of the PI3 kinase pathway and Akt | [78] |
CDKN2A | tumor suppressor genes | Encode the cell cycle inhibitor P16CDKN2A | Disruption of the function of p16INK4a and p14ARF effecting two cell cycle regulatory pathways, the p53 and the RB1 pathways | [79] |
Role of epigenetic in melanoma development and pathogenesis
Epigenetic Mechanisms | Type | Regulatory Protein | Biomarker Gene/Protein | Modification Context/Function | Expression Changes | Refs. |
---|---|---|---|---|---|---|
Chromatin Modifications | Writer | DNA methyltransferases (DNMTs) | Preferentially Expressed Antigen in Melanoma (PRAME) | Hypomethylation of specific CpG sites being close to the PRAME promoter leading to transcriptional activation | Up-regulated | [218] |
Deleted Split hand/Split foot 1 (DSS1) | Hypomethylation of gene giving rise to high expression level of DSS1 | Up-regulated | [219] | |||
Telomerase reverse transcriptase (TERT) | Hypermethylation of CpG islands leading to e inactivation of tumor suppressor gene | Down-regulated | [220] | |||
Ras association domain family 1 isoform A (RASSF1A) | Hypermethylation of promoter sites of this gene, which lead to cell-cycle development block from the G1 to the S phase | Down-regulated | [221] | |||
P16INK4A(CDKN2A) | Hypermethylation of P16INK4A is frequently associated with gene inactivation and the inhibition of CDK4/6 | Down-regulated | [220] | |||
BRCA1-associated protein-1 (BAP1) | Hypermethylation leads to BAP1 loss leading to large-scale methylomic repatterning | Down-regulated | [220] | |||
The feline sarcoma (FES) | Hypomethylation of gene leading to melanocytic hyperproliferation | Down-regulated | [222] | |||
P14ARF (CDKN2A) | Hypermethylation of CpG islands leading to e inactivation of tumor suppressor gene | Down-regulated | [223] | |||
PTEN | Hypermethylation of gene suppressing the PI3K/AKT pathway | Down-regulated | [224] | |||
Retinoic acid receptor (RAR)-β2 | Hypermethylation of specific tumor suppressor gene promoter | Down-regulated | [225] | |||
Microphthalmia-associated transcription factor (MITF) | Hypermethylation of gene leading to intrinsically low MITF expression | Down-regulated | [226] | |||
Eraser | DNMT or ten-eleven translocation (TET) methylcytosine dioxygenases | TBC1D16 | Hypomethylation in metastatic melanoma tumor tissues | Up-regulated | [227] | |
Reader | Methyl CpG binding proteins (MBPs) | MAGE-A | Hypermethylation of promoter has key role in restricting expression of the tumor-associated MAGE antigens | Down-regulated | [228] | |
Histone Modifications | Writer | Histone lysine methyltransferase (HKMTase) | Enhancer of zeste homolog 2 (EZH2) | Trimethylation of lysine 27 of histone H3 (H3K27me3) leading to transcriptional silencing of tumor suppressor genes | Up-regulated | [141] |
SET domain bifurcated 1 (SETDB1) | Trimethylation of lysine 9 of histone H3 (H3K9me3me3) leading to activation of thombospondin-1 (THBS1), and metastasis formation in melanoma | Up-regulated | [229] | |||
KMT2D | Monomethylation of lysine 4 of Histone H3(H3K4) deregulating particular promoter and genes in NRAS-mutant melanoma | Up-regulated | [230] | |||
EHMT | Mono/dimethylation of lysine 9 of histone 3(H3K9) | Up-regulated | [231] | |||
Histone acetyltransferases (HATs) | p300/CBP | Acetylation of lysine 27 of histone 3 (H3K27Ac) | variable | [232] | ||
Calmodulin-dependent protein kinase II (CaMKII) | cellular FADD-like, IL-β1-converting enzyme-inhibitory protein (c-FLIP) | Phosphorylation of c-FLIP upregulates its expression, thus making melanoma cells resistant to TRAIL-induced apoptosis | Up-regulated | [233] | ||
Protein arginine methyltransferases 1 (PRMT1) | Activated leukocyte cell adhesion molecule (ALCAM) | Arginine methylation of histones by PRMT1 regulating tumor growth and metastasis through targeting ALCAM | Up-regulated | [234] | ||
Reader | Bromodomain and extra-terminal domain proteins (BETs) | BRD2, BRD4 | Acetylated lysine residues of histones are bound by BETs | Up-regulated | [235] | |
Eraser | Histone Deacetylases (HDACs) | HDAC6 | Deacetylation of related substares cause JAK/STAT3 and PD-L1 expression | Up-regulated | [236] | |
HDAC1 | Deacetylation of histones or non-histones substrates gives rise to increasing tumor cell growth | Up-regulated | [237] | |||
HDAC3 | Deacetylation of histones or non-histones substrates cause increasing tumor cell growth | Up-regulated | [125] | |||
HDAC8 | Deacetylation mediates adaptation of melanoma cells to multiple stress like BRAF inhibitor tolerance | Up-regulated | [151] | |||
Histone Demethylases (HMDs) | JARID1B (KDM5B) | Demethylates histone 3 at the position 4 lysine residue (H3K4) | Up-regulated (only in nevi) | [238] | ||
JMJD3 (KDM6B) | Demethylates histone 3 at the position 27 lysine residue (H3K27) changes microenvironment of melanoma tumorsand enhances tumor progression | Up-regulated | [238] | |||
LSD1 (KDM1A) | Demethylates histone 3 on lysine residues at positions 4 and 9 (H3K4 and H3K9) | Up-regulated | [239] | |||
Non-coding RNA | – | snoRNA | miR-221 | Sustaining proliferative signaling | Up-regulated | |
miR-193b | Sustaining proliferative signaling | Up-regulated | ||||
miR-449a | Cell cycle exit and epidermis differentiation | Up-regulated | ||||
miR-205 | Enabling replicative immortality | Down-regulated | ||||
miR-18b | Resisting cell death | Down-regulated | ||||
miR-214 | Activating invasion and metastasis | Up-regulated | ||||
lncRN | HOX transcript antisense RNA (HOTAIR) | Promoting proliferation of malignant melanoma cells via NF-κB pathway | Up-regulated | [241] | ||
SPRY4-IT1 | Interacting with the PRC2 favoring the tri-methylation of H3K27 at specific target genes silencing of metastatic suppressor genes | Up-regulated | [209] | |||
Long:BRAF-activated ncRNA (BANCR) | Regulating both apoptosis and differentiation in melanoma | Up-regulated | [242] | |||
SAMMSON (survival associated mitochondrial melanoma-specific oncogenic lncRNA) | Maintainng oxidative phosphorylation and mitochondrial homeostasis | Up-regulated | [243] | |||
The metastasis‐associated lung adenocarcinoma transcript 1 (MALAT1) | Playing an oncogenic role in tumorigenesis via enhancing cancer‐cell proliferation, migration and invasion | Up-regulated | [244] | |||
Llme23 | Playing an oncogenic role in human melanoma via direct binding to PSF | Up-regulated | [245] | |||
Chromatin remodeling | The SWI/SNF (switch/sucrose non-fermenting) complex | ARID2, ARID1A ARID1B, SMARCA4, SMARCA2 | Mutations in SWI/SNF components affecting its activity | Up-regulated | [246] | |
BRG1 | Microphthalmia associated transcription factor (MITF) and SOX10 actively recruit BRG1 to chromatin for establishing the epigenetic landscape of proliferative melanoma | Up-regulated | [246] | |||
ATRX | Interaction of ATRX with macroH2A to negatively induce its association with chromatin | Down-regulated | [247] | |||
NuRF chromatin remodeling complex | BPTF | Elevating BPTF expression has link to poor prognosis and acquisition of resistance to BRAF inhibitors | Up-regulated | [248] | ||
Polycomb repressive complex 2 (PRC2) | EZH2 | Association with the beginning of a transcriptionally repressed state by the tri-methylation of H3 at lysine 27 | Up-regulated | [249] | ||
Chromatin assembly factor-1 (CAF-1) | p60 subunit | Acting in strict association with both the S-phase and DNA repair processes | Up-regulated | [250] | ||
Histone variants | MacroH2A | – | MacroH2A has ability of suppressing melanoma development through transcriptional repression of CDK8 | Up-regulated | [251] | |
H3.3 | – | E2F target genes repression | Up-regulated | [252] | ||
H2A.Z.2 | – | Promoting cell cycle progression | Up-regulated | [253] |